D. Boral Capital Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its price objective lowered by investment analysts at D. Boral Capital from $5.00 to $4.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other brokerages have also issued reports on PSTV. HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Plus Therapeutics in a research note on Wednesday, November 26th. Ascendiant Capital Markets decreased their price objective on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research lowered shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Plus Therapeutics Stock Performance

PSTV stock opened at $0.29 on Thursday. Plus Therapeutics has a one year low of $0.16 and a one year high of $2.31. The firm has a 50-day simple moving average of $0.54 and a two-hundred day simple moving average of $0.54. The firm has a market cap of $40.53 million, a price-to-earnings ratio of -0.15 and a beta of 0.85.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, equities analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Plus Therapeutics

Several institutional investors have recently modified their holdings of the stock. Altium Capital Management LLC acquired a new position in shares of Plus Therapeutics during the 3rd quarter worth about $628,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics during the third quarter valued at approximately $100,000. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics in the second quarter valued at approximately $41,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the third quarter worth approximately $46,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.